[go: up one dir, main page]

MA42456A - Inhibiteurs de hpk1 et leurs procédés d'utilisation - Google Patents

Inhibiteurs de hpk1 et leurs procédés d'utilisation

Info

Publication number
MA42456A
MA42456A MA42456A MA42456A MA42456A MA 42456 A MA42456 A MA 42456A MA 42456 A MA42456 A MA 42456A MA 42456 A MA42456 A MA 42456A MA 42456 A MA42456 A MA 42456A
Authority
MA
Morocco
Prior art keywords
compounds
methods
formula
pharmaceutically acceptable
inhibitors
Prior art date
Application number
MA42456A
Other languages
English (en)
Other versions
MA42456B1 (fr
Inventor
Yunhui Lang
Radoslaw Laufer
Sze-Wan Li
Yong Liu
Grace Ng
Narendra Kumar B Patel
Heinz W Pauls
Peter Brent Sampson
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of MA42456A publication Critical patent/MA42456A/fr
Publication of MA42456B1 publication Critical patent/MA42456B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des composés de thiénopyridinone de formule (i) et des sels de ceux-ci pharmaceutiquement acceptables. Dans ces composés, l'un de x1, x2, et x3 est s et les deux autres sont chacun indépendamment cr, r et toutes les autres variables sont telles que définies dans la description. Ces composés sont connus pour inhiber l'activité de la kinase hpk1 et pour avoir une activité antitumorale in vivo. Ces composés peuvent être efficacement combinés avec des vecteurs pharmaceutiquement acceptables, ainsi qu'avec d'autres techniques immunomodulatrices, telles qu'une inhibition de points de contrôle ou des inhibiteurs de l'oxydation du tryptophane. Formule (i).
MA42456A 2015-06-25 2016-06-23 Inhibiteurs de hpk1 et leurs procédés d'utilisation MA42456B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562184348P 2015-06-25 2015-06-25
PCT/CA2016/050734 WO2016205942A1 (fr) 2015-06-25 2016-06-23 Inhibiteurs de hpk1 et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA42456A true MA42456A (fr) 2018-05-23
MA42456B1 MA42456B1 (fr) 2021-06-30

Family

ID=57584335

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42456A MA42456B1 (fr) 2015-06-25 2016-06-23 Inhibiteurs de hpk1 et leurs procédés d'utilisation

Country Status (26)

Country Link
US (3) US10501474B2 (fr)
EP (1) EP3322711B1 (fr)
JP (3) JP6898868B2 (fr)
KR (2) KR102740623B1 (fr)
CN (2) CN107922431B (fr)
AU (1) AU2016282289B2 (fr)
BR (2) BR112017027241B1 (fr)
CY (1) CY1124489T1 (fr)
DK (1) DK3322711T3 (fr)
EA (1) EA035421B1 (fr)
ES (1) ES2872555T3 (fr)
HR (1) HRP20210895T1 (fr)
HU (1) HUE054159T2 (fr)
IL (2) IL283353B (fr)
LT (1) LT3322711T (fr)
MA (1) MA42456B1 (fr)
MD (1) MD3322711T2 (fr)
MX (2) MX386480B (fr)
PL (1) PL3322711T3 (fr)
PT (1) PT3322711T (fr)
RS (1) RS61919B1 (fr)
SG (1) SG10202105964RA (fr)
SI (1) SI3322711T1 (fr)
SM (1) SMT202100324T1 (fr)
TW (1) TWI733679B (fr)
WO (1) WO2016205942A1 (fr)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3322711T3 (pl) * 2015-06-25 2021-10-25 University Health Network Inhibitory hpk1 i sposoby ich zastosowania
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
WO2018049214A1 (fr) 2016-09-09 2018-03-15 Incyte Corporation Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
IL292977A (en) 2016-09-09 2022-07-01 Incyte Corp Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
WO2018049191A1 (fr) 2016-09-09 2018-03-15 Incyte Corporation Dérivés de pyrazolopyridone en tant que modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
WO2018152220A1 (fr) * 2017-02-15 2018-08-23 Incyte Corporation Composés de pyrazolopyridine et leurs utilisations
WO2018167147A1 (fr) * 2017-03-15 2018-09-20 F. Hoffmann-La Roche Ag Azaindoles utilisés en tant qu'inhibiteurs de hpk1
MA48994A (fr) * 2017-03-30 2020-02-05 Hoffmann La Roche Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
CN110678466B (zh) 2017-03-30 2023-01-31 豪夫迈·罗氏有限公司 作为hpk1抑制剂的二氮杂萘类
EP3638669A1 (fr) 2017-06-13 2020-04-22 Bayer Pharma Aktiengesellschaft Dérivés de pyrrolopyridine substitués
CA3079060A1 (fr) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Derives de pyrrolopyridine substitues utilises en tant que modulateurs de map4k1 pour le traitement de maladies cancereuses
US20200246347A1 (en) 2017-06-13 2020-08-06 Bayer Pharma Aktiengesellschaft Substituted Pyrrolopyridine-Derivatives
US11427578B1 (en) 2017-07-18 2022-08-30 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
CN109721620B (zh) * 2017-10-27 2022-05-13 药捷安康(南京)科技股份有限公司 Hpk1抑制剂及其用途
JP7167146B2 (ja) * 2017-11-06 2022-11-08 ブリストル－マイヤーズ スクイブ カンパニー Ｈｐｋ１阻害剤として有用なイソフラノン化合物
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
LT3755703T (lt) * 2018-02-20 2022-10-10 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
JP7386841B2 (ja) * 2018-07-24 2023-11-27 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト イソキノリン化合物及びその使用
CN112533677A (zh) 2018-07-24 2021-03-19 豪夫迈·罗氏有限公司 萘啶化合物及其用途
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
MA53726A (fr) 2018-09-25 2022-05-11 Incyte Corp Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
CN113166062A (zh) * 2018-10-03 2021-07-23 豪夫迈·罗氏有限公司 8-氨基异喹啉化合物及其用途
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113227089B (zh) 2018-10-31 2024-07-05 吉利德科学公司 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
CN117105933A (zh) * 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
EP3894406A1 (fr) 2018-12-11 2021-10-20 Bayer Aktiengesellschaft Dérivés de pyrrolopyridine substitués
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
BR112021011571A2 (pt) * 2018-12-26 2021-08-31 Janssen Pharmaceutica Nv Compostos de tienopiridinona
CA3129772A1 (fr) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Inhibiteurs bicycliques de hpk1
WO2020193511A1 (fr) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Inhibiteurs de hpk1
US20220242870A1 (en) * 2019-05-17 2022-08-04 Voronoi Inc. Heterocycle-fused pyrimidine derivative and use thereof
EP3972695A1 (fr) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
JP7295283B2 (ja) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
TWI848141B (zh) 2019-07-04 2024-07-11 英屬開曼群島商百濟神州有限公司 及其用途
TW202116771A (zh) 2019-07-17 2021-05-01 英屬開曼群島商百濟神州有限公司 作為ｈｐｋ１抑制劑之三環化合物及其用途
EP4010338A1 (fr) * 2019-08-06 2022-06-15 Incyte Corporation Formes solides d'un inhibiteur d'hpk 1
US12215105B2 (en) * 2019-09-13 2025-02-04 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
CN112552293A (zh) * 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
EP4045083B1 (fr) 2019-10-18 2024-01-10 Forty Seven, Inc. Polythérapies pour le traitement de syndromes myélodysplasiques et de la leucémie myéloïde aiguë
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CN117736207A (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
JP7667745B2 (ja) * 2020-01-09 2025-04-23 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
EP4135695A4 (fr) * 2020-04-13 2024-05-15 University Health Network Procédés de traitement du syndrome de libération de cytokines
MX2022013619A (es) 2020-05-01 2022-11-16 Gilead Sciences Inc Compuestos de 2,4-dioxopirimidina que inhiben cd73.
BR112022022946A2 (pt) * 2020-05-11 2023-01-10 Univ Health Network Sal e formas cristalinas de 4-amino-5-(6-(4-metilpiperazin-1-il)-1h-benzo[d]imidazol-2-il)tieno[2,3-b]piridin-6(7h)-ona
WO2021249913A1 (fr) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft Dérivés de 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azétidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate et des composés apparentés servant d'inhibiteurs de map4k1 (hpk1) pour le traitement du cancer
CN113845531B (zh) * 2020-06-28 2025-06-27 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物、包含其的药物组合物、其制备方法及其用途
US11834467B2 (en) * 2020-09-28 2023-12-05 1ST Biotherapeutics, Inc. Substituted indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors
MX2023003731A (es) 2020-09-30 2023-04-24 Beigene Ltd Compuestos de 3-[(1h-pirazol-4-il)oxi]pirazin-2-amina como inhibidores de hpk1, y uso de los mismos.
US20230406864A1 (en) * 2020-11-09 2023-12-21 Merck Sharp & Dohme Llc 7-azole substituted 2-aminoquinazoline inhibitors of hpk1
WO2022111517A1 (fr) * 2020-11-24 2022-06-02 正大天晴药业集团股份有限公司 Composé thiénopyridone modifié au deutérium
CN114805330A (zh) * 2021-01-22 2022-07-29 苏州信诺维医药科技股份有限公司 Hpk1抑制剂、其制备方法、药物组合物及其应用
EP4288437A1 (fr) 2021-02-05 2023-12-13 Bayer Aktiengesellschaft Inhibiteurs de map4k1
CN114907377A (zh) * 2021-02-10 2022-08-16 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
WO2022174253A1 (fr) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Antagonistes de hpk1 et leurs utilisations
EP4301756A4 (fr) 2021-03-05 2025-02-26 Nimbus Saturn, Inc. Antagonistes de hpk1 et leurs utilisations
CN116888127B (zh) * 2021-03-10 2025-09-02 轩竹生物科技股份有限公司 三并环类hpk1抑制剂及其用途
CN116981666A (zh) * 2021-03-26 2023-10-31 江苏恒瑞医药股份有限公司 稠合四环类化合物、其制备方法及其在医药上的应用
US12071442B2 (en) 2021-03-29 2024-08-27 Nimbus Saturn, Inc. Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
WO2022226667A1 (fr) * 2021-04-30 2022-11-03 Ontario Institute For Cancer Research (Oicr) Composés aminopyridine substitués utilisés en tant qu'inhibiteurs de la kinase progénitrice hématopoïétique 1 (hpk1)
EP4330246A4 (fr) * 2021-04-30 2025-04-02 Ontario Institute for Cancer Research (OICR) Composés amino aza-hétéroaryles à substitution halo utilisés en tant qu'inhibiteurs de la kinase des progéniteurs hématopoïétiques 1 (hpk1)
AU2022267407A1 (en) * 2021-04-30 2023-11-09 Ontario Institute For Cancer Research (Oicr) Substituted amino aza-heteroaryl compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)
WO2022245671A1 (fr) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Méthodes d'utilisation de protéines de fusion flt3l-fc
WO2022253252A1 (fr) * 2021-06-03 2022-12-08 Silexon Biotech Co., Ltd. Composés hétérocycliques utiles en tant qu'inhibiteurs de hpk1
CN115433161A (zh) * 2021-06-04 2022-12-06 轶诺(浙江)药业有限公司 新型hpk1抑制剂及其制备方法和应用
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359415A1 (fr) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
CN117693503A (zh) 2021-07-20 2024-03-12 阿斯利康(瑞典)有限公司 作为hpk1抑制剂用于治疗癌症的经取代的吡嗪-2-甲酰胺
WO2023015199A1 (fr) * 2021-08-03 2023-02-09 Nimbus Saturn, Inc. Antagonistes de hpk1 et leurs utilisations
WO2023023942A1 (fr) * 2021-08-24 2023-03-02 Biofront Ltd (Cayman) Inhibiteurs de hpk1, compositions comprenant un inhibiteur de hpk1 et leurs procédés d'utilisation
WO2023057882A1 (fr) * 2021-10-05 2023-04-13 Pfizer Inc. Combinaisons de composés d'azalactam avec un antagoniste de liaison à l'axe pd-1 pour le traitement du cancer
KR20240093606A (ko) * 2021-10-15 2024-06-24 로몬드 테라퓨틱스 인코포레이티드 치환된 1H-피라졸로[4,3-c] 퀴놀린, 이의 제조 방법 및 용도
WO2023076983A1 (fr) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Dérivés de pyridine-3(2h)-one
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (fr) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Anticorps ciblant 5t4 et leurs utilisations
TW202333754A (zh) * 2021-12-17 2023-09-01 大陸商海思科醫藥集團股份有限公司 並環雜環衍生物及其在醫藥上的應用
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4452266A4 (fr) * 2021-12-22 2025-12-24 Univ Health Network Traitement de la leucémie myéloïde aiguë ou du lymphome
WO2023122615A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
WO2023138612A1 (fr) * 2022-01-19 2023-07-27 Silexon Ai Technology Co., Ltd. Composés hétérocycliques utiles en tant qu'inhibiteurs de hpk1
WO2023143384A1 (fr) * 2022-01-27 2023-08-03 四川海思科制药有限公司 Composé pour inhiber ou dégrader la kinase hpk1 et son utilisation médicale
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023151559A1 (fr) * 2022-02-08 2023-08-17 和径医药科技（上海）有限公司 Composé hétérocyclique, composition pharmaceutique le contenant et utilisation anti-tumorale associée
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
PE20250157A1 (es) 2022-04-21 2025-01-22 Gilead Sciences Inc Compuestos de modulacion de kras g12d
CN119384415A (zh) 2022-07-01 2025-01-28 吉利德科学公司 Cd73化合物
WO2024064668A1 (fr) 2022-09-21 2024-03-28 Gilead Sciences, Inc. POLYTHÉRAPIE ANTICANCÉREUSE PAR RAYONNEMENT IONISANT FOCAL ET PERTURBATION CD47/SIRPα
CN117624187B (zh) * 2022-11-17 2025-11-04 杭州阿诺生物医药科技有限公司 一种高效的hpk1降解剂化合物及其制备方法和应用
KR102855849B1 (ko) 2022-11-25 2025-09-08 충남대학교산학협력단 이미다조피리딘 유도체, 이를 유효성분으로 포함하는 약제학적 조성물 및 이를 이용하는 암의 치료 방법
US20240254118A1 (en) 2022-12-22 2024-08-01 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024206869A2 (fr) * 2023-03-30 2024-10-03 Board Of Regents, The University Of Texas System Combinaison d'inhibiteur de hpk1 et d'inhibiteur d'axl dans une thérapie anticancéreuse
KR20250167002A (ko) 2023-04-11 2025-11-28 길리애드 사이언시즈, 인코포레이티드 Kras 조절 화합물
CN121079300A (zh) 2023-04-21 2025-12-05 吉利德科学公司 Prmt5抑制剂及其用途
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (fr) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Inhibiteurs de parp7
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (fr) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Dérivés polycycliques contenant une pyrimidine utilisés comme composés de modulation de kras g12d
WO2025080099A1 (fr) * 2023-10-13 2025-04-17 주식회사유한양행 Dérivé 7,7-diméthylfuro[3,4-b] pyridin-5(7h)-one ou sel de celui-ci, et composition pharmaceutique le comprenant
WO2025096647A1 (fr) * 2023-10-30 2025-05-08 Nimbus Saturn, Inc. Méthodes de traitement de tumeurs
WO2025096589A1 (fr) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2025137640A1 (fr) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Inhibiteurs azaspiro de wrn
WO2025245003A1 (fr) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021615A1 (fr) * 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
WO2001028993A2 (fr) 1999-10-19 2001-04-26 Merck & Co. Inc. Inhibiteurs tyrosine kinase
ATE448226T1 (de) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
US8501750B2 (en) 2007-05-21 2013-08-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
MX2010011047A (es) * 2008-04-11 2010-10-26 Merck Patent Gmbh Derivados de tienopiridonas como activadores de proteina cinasa activada por amp (ampk).
MY160357A (en) 2008-05-05 2017-02-28 Merck Patent Gmbh Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
BR112013020329A2 (pt) 2011-02-09 2016-08-02 Hoffmann La Roche compostos heterocíclicos como inibidores da pi3-quinase
GB201114212D0 (en) * 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
PL3322711T3 (pl) * 2015-06-25 2021-10-25 University Health Network Inhibitory hpk1 i sposoby ich zastosowania

Also Published As

Publication number Publication date
JP2018522858A (ja) 2018-08-16
SMT202100324T1 (it) 2021-07-12
SI3322711T1 (sl) 2021-08-31
KR20240000617A (ko) 2024-01-02
AU2016282289B2 (en) 2020-12-24
MX2021011435A (es) 2021-10-13
EA201890059A1 (ru) 2018-07-31
EP3322711B1 (fr) 2021-03-10
JP6898868B2 (ja) 2021-07-07
IL256250B (en) 2021-06-30
KR102614872B1 (ko) 2023-12-15
JP7241810B2 (ja) 2023-03-17
BR112017027241B1 (pt) 2023-09-26
LT3322711T (lt) 2021-05-10
PT3322711T (pt) 2021-05-13
HRP20210895T1 (hr) 2021-08-20
EP3322711A4 (fr) 2018-12-19
CN113214287A (zh) 2021-08-06
CN113214287B (zh) 2023-10-20
CN107922431A (zh) 2018-04-17
MX386480B (es) 2025-03-18
TW201718597A (zh) 2017-06-01
EP3322711A1 (fr) 2018-05-23
IL283353B (en) 2022-09-01
US11059832B2 (en) 2021-07-13
US20200190104A1 (en) 2020-06-18
BR122023006150B1 (pt) 2023-12-12
NZ738268A (en) 2024-04-26
IL256250A (en) 2018-02-28
US20220002313A1 (en) 2022-01-06
CN107922431B (zh) 2021-06-04
CA2989684A1 (fr) 2016-12-29
US20180179221A1 (en) 2018-06-28
EA035421B1 (ru) 2020-06-11
JP2023071911A (ja) 2023-05-23
US10501474B2 (en) 2019-12-10
IL283353A (en) 2021-07-29
KR102740623B1 (ko) 2024-12-10
HK1255833A1 (en) 2019-08-30
MA42456B1 (fr) 2021-06-30
RS61919B1 (sr) 2021-06-30
SG10202105964RA (en) 2021-07-29
CY1124489T1 (el) 2022-07-22
PL3322711T3 (pl) 2021-10-25
TWI733679B (zh) 2021-07-21
ES2872555T3 (es) 2021-11-02
DK3322711T3 (en) 2021-04-26
JP2021138754A (ja) 2021-09-16
BR112017027241A2 (fr) 2018-08-21
MX2018000048A (es) 2018-06-06
KR20180015255A (ko) 2018-02-12
AU2016282289A1 (en) 2018-01-04
MD3322711T2 (ro) 2021-07-31
HUE054159T2 (hu) 2021-08-30
WO2016205942A1 (fr) 2016-12-29

Similar Documents

Publication Publication Date Title
MA42456A (fr) Inhibiteurs de hpk1 et leurs procédés d'utilisation
MA54229B1 (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA47079A (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
CR20210189A (es) Inhibidores de la proteina tirosina fosfatasa
WO2018112365A3 (fr) Procédés de traitement du cancer colorectal et d'un mélanome en utilisant parabacteroides goldsteinii
MA43131B1 (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA38175B1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA45920B1 (fr) Inhibiteurs de pyridopyrimidinone cdk2/4/6
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA38393A3 (fr) Composés hétéroaryle et utilisations associées
MA32134B1 (fr) Composés hétérocycliques
MA29909B1 (fr) Derives de pyridazine
MA29856B1 (fr) Derives de diacylindazole en tant qu'inhibiteurs de lipases et de phospholipases
MA41179A (fr) Composés inhibiteurs de parg
UA116774C2 (uk) Інгібітори серин/треонінкінази
MA34234B1 (fr) Composes pyrazol-4-yl-heterocyclyle-carboxamide et leurs procedes d'utilisation
MA43364B1 (fr) Composés d'alcènes tétrasubstitués et leur utilisation
MA42145A (fr) Triazoles agonistes du récepteur apj
MA39972B1 (fr) Composés et compositions d'induction de la chondrogenèse
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
PH12021552588A1 (en) Cd73 inhibitors
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton